Fadi Farhat

1.0k total citations
55 papers, 684 citations indexed

About

Fadi Farhat is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Fadi Farhat has authored 55 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 12 papers in Surgery. Recurrent topics in Fadi Farhat's work include Lung Cancer Treatments and Mutations (8 papers), Sarcoma Diagnosis and Treatment (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Fadi Farhat is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Sarcoma Diagnosis and Treatment (7 papers) and Colorectal Cancer Treatments and Studies (6 papers). Fadi Farhat collaborates with scholars based in Lebanon, United States and France. Fadi Farhat's co-authors include Joseph Kattan, Rami Mahfouz, Samir Nammour, Christine Théodore, Zaher K. Otrock, Ahmad Awada, Rim Ishak, Arafat Tfayli, Marie-Josée Terrier-Lacombe and Jean‐Pierre Droz and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Fadi Farhat

50 papers receiving 675 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fadi Farhat Lebanon 17 234 196 188 135 82 55 684
Marco Siano Switzerland 15 153 0.7× 297 1.5× 175 0.9× 93 0.7× 51 0.6× 43 639
Franchette W.P.J. van den Berkmortel Netherlands 16 169 0.7× 388 2.0× 142 0.8× 83 0.6× 123 1.5× 58 771
Martina Catalano Italy 16 270 1.2× 323 1.6× 215 1.1× 200 1.5× 91 1.1× 70 749
Yuichi Goto Japan 18 137 0.6× 313 1.6× 206 1.1× 266 2.0× 115 1.4× 80 924
Yutaka Sasaki Japan 13 244 1.0× 242 1.2× 340 1.8× 174 1.3× 137 1.7× 47 963
Zhiwei Chen China 19 353 1.5× 346 1.8× 301 1.6× 61 0.5× 127 1.5× 46 965
Lawrence Tan Canada 10 218 0.9× 203 1.0× 213 1.1× 100 0.7× 59 0.7× 30 590
Brieuc Sautois Belgium 13 171 0.7× 188 1.0× 150 0.8× 141 1.0× 42 0.5× 49 630
Maki Tanioka Japan 17 111 0.5× 335 1.7× 261 1.4× 124 0.9× 166 2.0× 76 841

Countries citing papers authored by Fadi Farhat

Since Specialization
Citations

This map shows the geographic impact of Fadi Farhat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fadi Farhat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fadi Farhat more than expected).

Fields of papers citing papers by Fadi Farhat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fadi Farhat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fadi Farhat. The network helps show where Fadi Farhat may publish in the future.

Co-authorship network of co-authors of Fadi Farhat

This figure shows the co-authorship network connecting the top 25 collaborators of Fadi Farhat. A scholar is included among the top collaborators of Fadi Farhat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fadi Farhat. Fadi Farhat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Macaron, Walid, et al.. (2022). Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. Current Problems in Cancer. 46(3). 100859–100859. 9 indexed citations
2.
Kattan, Joseph, Fadi Farhat, Georges Chahine, et al.. (2022). Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients. BMC Cancer. 22(1). 1114–1114. 4 indexed citations
3.
Zerdan, Maroun Bou, et al.. (2020). Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region. Cancer Treatment and Research Communications. 26. 100275–100275. 3 indexed citations
4.
Farhat, Fadi, Bassim Al Bahrani, Eman Sbaity, et al.. (2020). Comprehensive review into the challenges of gastrointestinal tumors in the Gulf and Levant countries. World Journal of Clinical Cases. 8(3). 487–503. 5 indexed citations
5.
Assi, Hazem, Fadi El Karak, Fadi Farhat, et al.. (2020). Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients. Journal of Oncology. 2020. 1–7. 4 indexed citations
6.
Saleh, Fatima, et al.. (2020). Detection of PIK3R1 (L449S) Mutation in a Patient with Ovarian Cancer: A Case Report. Case Reports in Oncology. 13(1). 188–192. 1 indexed citations
7.
Shamieh, Saïd El, et al.. (2019). Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer. Drug Metabolism and Personalized Therapy. 34(2). 7 indexed citations
8.
9.
Farhat, Fadi, et al.. (2017). The Concept of Biosimilars: From Characterization to Evolution—A Narrative Review. The Oncologist. 23(3). 346–352. 29 indexed citations
10.
Bahmad, Hisham F., et al.. (2017). Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature. Frontiers in Medicine. 4. 164–164. 19 indexed citations
11.
Tfayli, Arafat, Alain Mina, Hind Rafei, et al.. (2015). Screening for the Prevalence of EGFR and Alk Mutations in Lung Adenocarcinoma Patients in the Levant Area, a Prospective Analysis. Annals of Oncology. 26. i1–i1. 1 indexed citations
12.
Farhat, Fadi, Marwan Ghosn, & Joseph Kattan. (2015). Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 76(2). 235–242. 6 indexed citations
13.
Ishak, Rim, et al.. (2013). Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors. Critical Reviews in Oncology/Hematology. 90(2). 152–164. 43 indexed citations
14.
Ghosn, Marwan, et al.. (2012). Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer. Medical Oncology. 29(4). 2831–2837. 8 indexed citations
15.
Mahfouz, Rami, et al.. (2011). JAK2 V617F Gene Mutation in the Laboratory Work-Up of Myeloproliferative Disorders: Experience of a Major Referral Center in Lebanon. Genetic Testing and Molecular Biomarkers. 15(4). 263–265. 20 indexed citations
16.
17.
Farhat, Fadi, Joseph Kattan, & Marwan Ghosn. (2010). Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer. Expert Review of Anticancer Therapy. 10(4). 541–548. 8 indexed citations
18.
Nietert, Paul J., Mariam Arabi, Samar Muwakkit, et al.. (2009). Pulmonary hypertension in children and young adults with sickle cell disease: Evidence for familial clustering. Pediatric Blood & Cancer. 54(3). 398–402. 20 indexed citations
19.
Haidar, Rachid, Ghina R. Mumtaz, Roula Farah, et al.. (2008). Limb salvage surgery for children and adolescents with malignant bone tumors in a developing country. Pediatric Blood & Cancer. 51(6). 787–791. 19 indexed citations
20.
Ghosn, Marwan, et al.. (2007). Sequential vinorelbine–capecitabine followed by docetaxel in advanced breast cancer: long-term results of a pilot phase II trial. Cancer Chemotherapy and Pharmacology. 62(1). 11–18. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Siano Breakdown of academic impact, for papers by Franchette W.P.J. van den Berkmortel Breakdown of academic impact, for papers by Martina Catalano Breakdown of academic impact, for papers by Yuichi Goto Breakdown of academic impact, for papers by Yutaka Sasaki Breakdown of academic impact, for papers by Zhiwei Chen Breakdown of academic impact, for papers by Lawrence Tan Breakdown of academic impact, for papers by Brieuc Sautois Breakdown of academic impact, for papers by Maki Tanioka
Rankless by CCL
2026